The synergistic effect between KLVFF and self-assembly chaperones on both disaggregation of beta-amyloid fibrils and reducing consequent toxicity.

By combining KLVFF peptide and self-assembly chaperone we fabricate a new system to achieve the synchronization between Aβ fibril disaggregation and reducing toxicity of Aβ fragments (monomers or oligomers) that consequently formed. When the KLVFF peptides disaggregate fibrils into fragments, the hydrophobic domains of self-assembly chaperones promptly bind them at the same time. This binding blocks the re-aggregation of the fragments and their interaction with cells, and hence reduces the toxicity of these dangerous fragments.

[1]  Huadong Zhou,et al.  Immunotherapy for Alzheimer disease—the challenge of adverse effects , 2012, Nature Reviews Neurology.

[2]  L. Tjernberg,et al.  Arrest of -Amyloid Fibril Formation by a Pentapeptide Ligand (*) , 1996, The Journal of Biological Chemistry.

[3]  Huaxi Xu,et al.  Insulin-degrading enzyme sorting in exosomes: a secretory pathway for a key brain amyloid-beta degrading protease. , 2010, Journal of Alzheimer's disease : JAD.

[4]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[5]  W. Pardridge,et al.  Disaggregation of amyloid plaque in brain of Alzheimer's disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide. , 2013, Molecular pharmaceutics.

[6]  T. Saido,et al.  Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition , 2000, Nature Medicine.

[7]  N. Inestrosa,et al.  Hyperforin prevents β-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-β-deposits , 2006, Molecular Psychiatry.

[8]  M. Lindgren,et al.  Detection and characterization of aggregates, prefibrillar amyloidogenic oligomers, and protofibrils using fluorescence spectroscopy. , 2005, Biophysical journal.

[9]  M. Citron,et al.  Alzheimer's disease: strategies for disease modification , 2010, Nature Reviews Drug Discovery.

[10]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[12]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[13]  B. Solomon,et al.  Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[14]  L. K. Baker,et al.  Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability* , 2002, The Journal of Biological Chemistry.

[15]  Yan-Jiang Wang,et al.  Alzheimer disease: Lessons from immunotherapy for Alzheimer disease , 2014, Nature Reviews Neurology.

[16]  L. Kiessling,et al.  Recognition sequence design for peptidyl modulators of beta-amyloid aggregation and toxicity. , 1999, Biochemistry.

[17]  E. Siemers,et al.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[18]  C. Dobson,et al.  Protein aggregation and amyloid fibril formation by an SH3 domain probed by limited proteolysis. , 2003, Journal of molecular biology.

[19]  T. Govindaraju,et al.  Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer's disease. , 2015, Chemical communications.

[20]  Nick C Fox,et al.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[21]  P. Muchowski,et al.  Modulation of neurodegeneration by molecular chaperones , 2005, Nature Reviews Neuroscience.

[22]  F. Baas,et al.  Branched KLVFF Tetramers Strongly Potentiate Inhibition of β‐Amyloid Aggregation , 2007, Chembiochem : a European journal of chemical biology.

[23]  Krystal R. Fontenot,et al.  Effects of peptides derived from terminal modifications of the aβ central hydrophobic core on aβ fibrillization. , 2010, ACS chemical neuroscience.

[24]  Linqi Shi,et al.  Cooperative macromolecular self-assembly toward polymeric assemblies with multiple and bioactive functions. , 2014, Accounts of chemical research.

[25]  B. Solomon,et al.  Disaggregation of Alzheimer β-amyloid by site-directed mAb , 1997 .

[26]  M. Leissring,et al.  Proteolytic degradation of amyloid β-protein. , 2012, Cold Spring Harbor perspectives in medicine.

[27]  Linqi Shi,et al.  Maintenance of amyloid β peptide homeostasis by artificial chaperones based on mixed-shell polymeric micelles. , 2014, Angewandte Chemie.

[28]  M. Mattson.  Pathways towards and away from Alzheimer's disease , 2004, Nature.

[29]  H. Levine,et al.  Thioflavine T interaction with synthetic Alzheimer's disease β‐amyloid peptides: Detection of amyloid aggregation in solution , 1993, Protein science : a publication of the Protein Society.

[30]  K. Oka,et al.  Photodegradation of amyloid β and reduction of its cytotoxicity to PC12 cells using porphyrin derivatives. , 2014, Chemical communications.

[31]  I. Tothill,et al.  Detection of β-amyloid peptide (1-16) and amyloid precursor protein (APP770) using spectroscopic ellipsometry and QCM techniques: a step forward towards Alzheimers disease diagnostics. , 2010, Biosensors & bioelectronics.

[32]  L. Mucke,et al.  Alzheimer Mechanisms and Therapeutic Strategies , 2012, Cell.

[33]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[34]  C. Dobson,et al.  Protein misfolding, functional amyloid, and human disease. , 2006, Annual review of biochemistry.

[35]  Linqi Shi,et al.  Self-regulated multifunctional collaboration of targeted nanocarriers for enhanced tumor therapy. , 2014, Biomacromolecules.

[36]  A. Bush,et al.  Sequestration of Copper from β-Amyloid Promotes Selective Lysis by Cyclen-Hybrid Cleavage Agents* , 2008, Journal of Biological Chemistry.

[37]  Xiaogang Qu,et al.  Using Graphene Oxide High Near‐Infrared Absorbance for Photothermal Treatment of Alzheimer's Disease , 2012, Advanced materials.

[38]  Shaomin Li,et al.  Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.

[39]  Seth Love,et al.  Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.

[40]  T. Saido,et al.  Reply to: 'Clearance of amyloid β-peptide from brain: transport or metabolism?' , 2000, Nature Medicine.

[41]  Y. Kawata,et al.  Evaluation of Aβ fibrillization inhibitory effect by a PEG-peptide conjugate based on an Aβ peptide fragment with intramolecular FRET. , 2011, Chemical communications.

[42]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[43]  Andreas Bracher,et al.  Molecular chaperones in protein folding and proteostasis , 2011, Nature.